光峯科技(688007.SH):獨立研發的AR模組暫未應用到蘋果新近發佈的MR產品中
格隆匯6月16日丨有投資者向光峯科技(688007.SH)提問,“近期蘋果MR將採用漸成趨勢的“超短焦光學摺疊光路”(Pancake)方案,能夠大幅減少AR/VR鏡頭體積,具有成像品質更好、畫面畸變小、可調節屈光度等優點,將顯著提升用户體驗感和佩戴舒適度。請問貴公司“”零後焦”技術和全球首個PPI破萬光學模組(特別適用於AR眼鏡),是否適用於蘋果MR?或者是否有已經和蘋果展開相關合作?”
光峯科技回覆稱,公司獨立研發的AR模組暫未應用到蘋果新近發佈的MR產品中。AR顯示是公司中長期探索方向之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.